Gsk Plc-spon Adr. (GSK)

$39.27

-0.33

(-0.83%)▲

Market is closed - opens 7 PM, 19 Apr 2024

Insights on Gsk Plc-spon Adr.

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 8.14B → 8.05B (in $), with an average decrease of 1.2% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 3 quarters, 1.62B → 350.0M (in $), with an average decrease of 43.0% per quarter

  • Vs LLY

    In the last 1 year, Eli Lilly And Company has given 103.0% return, outperforming this stock by 95.3%

  • Vs LLY

    In the last 3 years, Eli Lilly And Company has given 296.7% return, outperforming this stock by 312.8%

Performance

  • $39.16
    $39.49
    $39.27
    downward going graph

    0.29%

    Downside

    Day's Volatility :0.85%

    Upside

    0.56%

    downward going graph
  • $32.35
    $43.84
    $39.27
    downward going graph

    17.62%

    Downside

    52 Weeks Volatility :26.21%

    Upside

    10.42%

    downward going graph

Returns

PeriodGsk Plc-spon Adr.Russel 2000Index (Russel 2000)
3 Months
0.15%
0.0%
0.0%
6 Months
9.12%
0.0%
0.0%
1 Year
7.67%
-1.5%
-1.5%
3 Years
-16.59%
-21.8%
-21.8%

Highlights

Market Capitalization
84.3B
Book Value
$3.29
Dividend Share
0.58
Dividend Yield
3.62%
Earnings Per Share (EPS)
2.99
PE Ratio
13.55
PEG Ratio
1.09
Wall Street Target Price
44.1
Profit Margin
16.25%
Operating Margin TTM
20.36%
Return On Assets TTM
8.81%
Return On Equity TTM
46.38%
Revenue TTM
30.3B
Revenue Per Share TTM
14.97
Quarterly Revenue Growth YOY
9.2%
Gross Profit TTM
19.9B
EBITDA
10.3B
Diluted Eps TTM
2.99
Quarterly Earnings Growth YOY
-0.77
EPS Estimate Current Year
3.95
EPS Estimate Next Year
4.55
EPS Estimate Current Quarter
0.76
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    48%Buy
    39%Hold
    12%Sell
Based on 33 Wall street analysts offering stock ratings for Gsk Plc-spon Adr.(by analysts ranked 0 to 5 stars)
Based on 33 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
16
16
15
Hold
13
13
15
Sell
4
4
4

Analyst Forecast

What analysts predicted

Upside of 12.3%

Current $39.27
Target $44.10

Company Financials

FY18Y/Y Change
Revenue
39.1B
↑ 2.1%
Net Income
4.6B
↑ 136.49%
Net Profit Margin
11.75%
↑ 6.67%
FY19Y/Y Change
Revenue
44.3B
↑ 9.52%
Net Income
6.1B
↑ 28.21%
Net Profit Margin
13.76%
↑ 2.01%
FY20Y/Y Change
Revenue
46.5B
↑ 1.02%
Net Income
7.8B
↑ 23.77%
Net Profit Margin
16.86%
↑ 3.1%
FY21Y/Y Change
Revenue
46.1B
↑ 0.04%
Net Income
5.9B
↓ 23.73%
Net Profit Margin
12.85%
↓ 4.01%
FY22Y/Y Change
Revenue
29.3B
↓ 14.04%
Net Income
4.9B
↑ 12.22%
Net Profit Margin
16.78%
↑ 3.93%
FY23Y/Y Change
Revenue
38.6B
↑ 3.42%
Net Income
6.3B
↑ 0.14%
Net Profit Margin
16.25%
↓ 0.53%
Q3 FY22Q/Q Change
Revenue
8.7B
↑ 12.99%
Net Income
870.1M
↓ 7.04%
Net Profit Margin
9.95%
↓ 2.14%
Q4 FY22Q/Q Change
Revenue
7.4B
↓ 5.79%
Net Income
1.5B
↑ 87.55%
Net Profit Margin
19.81%
↑ 9.86%
Q1 FY23Q/Q Change
Revenue
8.6B
↓ 5.76%
Net Income
1.8B
↑ 1.98%
Net Profit Margin
21.44%
↑ 1.63%
Q2 FY23Q/Q Change
Revenue
9.1B
↑ 3.27%
Net Income
2.0B
↑ 8.99%
Net Profit Margin
22.62%
↑ 1.18%
Q3 FY23Q/Q Change
Revenue
8.1B
↑ 13.5%
Net Income
1.5B
↓ 9.85%
Net Profit Margin
17.97%
↓ 4.65%
Q4 FY23Q/Q Change
Revenue
10.3B
↓ 1.17%
Net Income
445.6M
↓ 76.09%
Net Profit Margin
4.35%
↓ 13.62%
FY18Y/Y Change
Total Assets
73.7B
↑ 2.99%
Total Liabilities
69.0B
↑ 2.84%
FY19Y/Y Change
Total Assets
104.5B
↑ 37.24%
Total Liabilities
80.4B
↑ 12.76%
FY20Y/Y Change
Total Assets
109.6B
↑ 0.93%
Total Liabilities
81.3B
↓ 2.79%
FY21Y/Y Change
Total Assets
106.8B
↓ 1.65%
Total Liabilities
78.0B
↓ 3.12%
FY22Y/Y Change
Total Assets
60.1B
↓ 23.96%
Total Liabilities
50.1B
↓ 13.35%
FY23Y/Y Change
Total Assets
75.1B
↓ 1.9%
Total Liabilities
58.8B
↓ 7.67%
Q3 FY22Q/Q Change
Total Assets
67.4B
↓ 32.27%
Total Liabilities
57.6B
↓ 22.3%
Q4 FY22Q/Q Change
Total Assets
60.1B
↓ 0.28%
Total Liabilities
50.1B
↓ 3.0%
Q1 FY23Q/Q Change
Total Assets
72.6B
↓ 2.58%
Total Liabilities
58.6B
↓ 5.53%
Q2 FY23Q/Q Change
Total Assets
75.0B
↑ 1.48%
Total Liabilities
59.7B
↑ 0.04%
Q3 FY23Q/Q Change
Total Assets
60.9B
↑ 2.36%
Total Liabilities
48.2B
↑ 1.99%
Q4 FY23Q/Q Change
Total Assets
75.1B
↓ 3.05%
Total Liabilities
58.8B
↓ 4.21%
FY18Y/Y Change
Operating Cash Flow
10.7B
↑ 21.73%
Investing Cash Flow
-2.0B
↑ 7.62%
Financing Cash Flow
-8.1B
↑ 0.14%
FY19Y/Y Change
Operating Cash Flow
10.5B
↓ 4.76%
Investing Cash Flow
-7.0B
↑ 244.75%
Financing Cash Flow
-2.4B
↓ 71.2%
FY20Y/Y Change
Operating Cash Flow
11.5B
↑ 5.25%
Investing Cash Flow
2.9B
↓ 140.36%
Financing Cash Flow
-13.8B
↑ 450.65%
FY21Y/Y Change
Operating Cash Flow
10.7B
↓ 5.79%
Investing Cash Flow
-2.4B
↓ 182.23%
Financing Cash Flow
-10.2B
↓ 25.1%
FY22Y/Y Change
Operating Cash Flow
7.4B
↓ 6.9%
Investing Cash Flow
-8.8B
↑ 393.64%
Financing Cash Flow
823.0M
↓ 110.84%
Q3 FY22Q/Q Change
Operating Cash Flow
1.5B
↓ 19.2%
Investing Cash Flow
-4.6B
↓ 1.06%
Financing Cash Flow
-1.5B
↓ 70.44%
Q4 FY22Q/Q Change
Operating Cash Flow
1.9B
↑ 44.21%
Investing Cash Flow
-8.8B
↑ 114.26%
Financing Cash Flow
-1.3B
↑ 0.9%
Q1 FY23Q/Q Change
Operating Cash Flow
65.7M
↓ 97.22%
Investing Cash Flow
-505.4M
↓ 95.35%
Financing Cash Flow
-393.9M
↓ 76.23%
Q2 FY23Q/Q Change
Operating Cash Flow
1.6B
↑ 2366.04%
Investing Cash Flow
-1.7B
↑ 236.27%
Financing Cash Flow
39.1M
↓ 109.75%
Q3 FY23Q/Q Change
Operating Cash Flow
2.2B
↑ 69.24%
Investing Cash Flow
-1.9B
↑ 35.79%
Financing Cash Flow
-1.8B
↓ 5783.87%

Technicals Summary

Sell

Neutral

Buy

Gsk Plc-spon Adr. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Gsk Plc-spon Adr.
Gsk Plc-spon Adr.
-6.03%
9.12%
7.67%
-16.59%
-20.5%
Eli Lilly And Company
Eli Lilly And Company
-1.56%
23.64%
102.96%
295.89%
551.71%
Johnson & Johnson
Johnson & Johnson
-7.65%
-5.21%
-10.09%
-11.01%
5.27%
Merck & Co. Inc.
Merck & Co. Inc.
3.24%
22.92%
9.18%
61.43%
71.29%
Abbvie Inc
Abbvie Inc
-7.98%
10.03%
2.92%
51.23%
111.74%
Pfizer Inc.
Pfizer Inc.
-8.3%
-19.07%
-37.31%
-34.7%
-35.45%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Gsk Plc-spon Adr.
Gsk Plc-spon Adr.
13.55
13.55
1.09
3.95
0.46
0.09
0.04
3.29
Eli Lilly And Company
Eli Lilly And Company
128.31
128.31
1.43
12.51
0.48
0.12
0.01
11.98
Johnson & Johnson
Johnson & Johnson
27.78
27.78
0.89
10.65
0.18
0.08
0.03
28.57
Merck & Co. Inc.
Merck & Co. Inc.
893.29
893.29
0.1
8.56
0.01
0.03
0.02
14.85
Abbvie Inc
Abbvie Inc
59.98
59.98
0.45
11.11
0.35
0.08
0.04
5.87
Pfizer Inc.
Pfizer Inc.
69.43
69.43
0.26
2.21
0.02
0.02
0.07
15.77
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Gsk Plc-spon Adr.
Gsk Plc-spon Adr.
Buy
$84.3B
-20.5%
13.55
16.25%
Eli Lilly And Company
Eli Lilly And Company
Buy
$713.8B
551.71%
128.31
15.36%
Johnson & Johnson
Johnson & Johnson
Hold
$348.1B
5.27%
27.78
41.28%
Merck & Co. Inc.
Merck & Co. Inc.
Buy
$316.8B
71.29%
893.29
0.61%
Abbvie Inc
Abbvie Inc
Buy
$287.8B
111.74%
59.98
8.95%
Pfizer Inc.
Pfizer Inc.
Buy
$145.5B
-35.45%
69.43
3.62%

Institutional Holdings

  • Dodge & Cox

    3.38%

  • FMR Inc

    0.95%

  • Fisher Asset Management, LLC

    0.74%

  • T. Rowe Price Associates, Inc.

    0.63%

  • JTC Employer Solutions Trustee Ltd

    0.60%

  • PRIMECAP Management Company

    0.59%

Corporate Announcements

  • Gsk Plc-spon Adr. Dividends March,2024

    In the quarter ending March,2024. Gsk Plc-spon Adr. has declared dividend of $0.41

    Read More

Company Information

GSK plc, formerly GlaxoSmithKline plc, is a British multinational pharmaceutical and biotechnology company with global headquarters in London, England.

Organization
Gsk Plc-spon Adr.
Employees
70212
CEO
Ms. Emma Natasha Walmsley
Industry
Health Technology

Discover More

FAQs